iOnctura is a life sciences company focused on developing high-impact, low-disruption therapies designed to extend healthspan. The company’s mission is to develop treatments by disrupting the dynamic interplay at the tumor-stroma-immune interface, aiming to create more effective options for patients facing challenging cancers.
On its website, iOnctura states that it targets neglected and hard-to-treat cancers, where conventional therapies can produce unwelcome side effects. Its approach is centered on creating precision oral small-molecule treatments with the goal of being less toxic while maintaining or improving efficacy. The company also describes an active clinical pipeline, including programs such as roginolisib (IOA-244), Cambritaxestat (IOA-289), and IOA-359 - each described in terms of its biological target and intended mechanism of action.